Population size, HIV prevalence, and antiretroviral therapy coverage among key

populations in sub-Saharan Africa: collation and synthesis of survey data 2010-2023

- Oliver Stevens MPH^{§1}, Keith Sabin PhD², Rebecca Anderson BSc¹, Sonia Arias Garcia
- MSc², Kalai Willis MSPH³, Amrita Rao PhD³, Anne F. McIntyre PhD⁴, Elizabeth Fearon
- 5 PhD⁵, Emilie Grard MPH¹, Alice Stuart-Brown MSc¹, Prof Frances Cowan MD^{6,7}, Prof
- 6 Louisa Degenhardt PhD⁸, James Stannah MPH¹³, Jinkou Zhao PhD⁹, Avi J. Hakim
- PhD⁴, Katherine Rucinski PhD³, Isabel Sathane BSc¹⁰, Makini Boothe PhD¹¹, Lydia
- 8 Atuhaire PhD¹², Prof Peter S. Nyasulu PhD^{12,13}, Mathieu Maheu-Giroux ScD¹⁴, Prof
- 9 Lucy Platt PhD¹⁵, Brian Rice PhD¹⁶, Wolfgang Hladik MD⁴, Prof Stefan Baral MD³, Mary
- 10 Mahy ScD², Jeffrey W. Imai-Eaton PhD^{1, 17}
- MRC Centre for Global Infectious Disease Analysis, School of Public Health,
 Imperial College London, London, United Kingdom
- Data for Impact, The Joint United Nations Program on HIV/AIDS (UNAIDS), Geneva, Switzerland
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- ^{4.} US Centers for Disease Control and Prevention (CDC), Atlanta, USA
- ^{5.} Institute for Global Health, University College London, London, United Kingdom
- Liverpool School of Tropical Medicine, Liverpool, United Kingdom
 - Centre for Sexual Health and HIV/AIDS Research, Zimbabwe
- National Drug & Alcohol Research Centre, University New South Wales, Sydney,
 Australia
- The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
- ^{10.} Ministry of Health, Maputo, Mozambique

- Data for Impact, The Joint United Nations Program on HIV/AIDS (UNAIDS), Maputo,
 Mozambique
- Division of Epidemiology & Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- Division of Epidemiology & Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Department of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, Canada
- ^{15.} Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom

- Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, United Kingdom
- Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
- 41 § Correspondence to:
- 42 Oliver Stevens
- 43 MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial
- 44 College London
- St. Mary's Hospital Campus
- 46 Norfolk Place
- 47 London

34

35

38 39 40

- 48 W2 1PG
- 49 United Kingdom
- o.stevens@imperial.ac.uk

Abstract

coverage for mainland SSA.

Background: Key population HIV programmes in sub-Saharan Africa (SSA) require
epidemiologic information to ensure equitable and equal access to services. We
consolidated survey data among female sex workers (FSW), men-who-have-sex-withmen (MSM), people who inject drugs (PWID), and transgender people to estimate
national-level key population size, HIV prevalence, and antiretroviral therapy (ART)

Methods: Key population size estimates (KPSE), HIV prevalence, and ART coverage data from 39 SSA countries between 2010-2022 were collated from existing databases and verified against source documents. We used Bayesian mixed-effects spatial regression to model urban KPSE as a proportion of the gender-matched 15-49 years adult population. We modelled subnational key population HIV prevalence and ART coverage with age/gender/year/province-matched total population estimates as predictors.

Findings: We extracted 2062 unique KPSE, 1243 HIV prevalence, and 201 ART coverage data points. Across national urban populations, a median of 1.71% of women were FSW (interquartile range [IQR]=1.21-1.97%); 0.92% of men were MSM (IQR=0.73-1.01%); 0.32% of men injected drugs (IQR=0.28-0.39%), and 0.14% of women were transgender (IQR=0.12-0.17%). Key population HIV prevalence was 4 to 6 times higher than gender-matched total population prevalence. ART coverage was correlated with, but lower than, total population ART coverage. Across SSA, key

- populations were estimated as 1.3% (95%CI: 0.9-1.7%) of the total population aged 15-
- 49 years but 6.3% (4.6-8.6%) of people living with HIV.
- ⁷⁵ Interpretation: Key populations in SSA experience disproportionately higher HIV
- burden and lower ART coverage, underscoring a need for focused prevention and
- treatment services. However, data availability and heterogeneity limit precise estimates
- for programming and monitoring trends. Strengthening key population surveys and
- routine data within national HIV strategic information systems would support more
- precise estimates.
- 81 Funding: UNAIDS, BMGF, NIH

Research in Context

82

Evidence before this study 83 Key populations, including female sex workers (FSW), men who have sex with men 84 (MSM), people who inject drugs (PWID), and transgender populations, are at high risk 85 of HIV globally, including in sub-Saharan Africa (SSA). Delivering appropriate HIV 86 prevention and treatment programming to these populations, and monitoring attainment 87 of an equitable HIV response, requires robust information on key population size, HIV 88 prevalence, the treatment cascade, and new HIV infections. For this reason, key 89 population surveys, including population size estimation and bio-behavioural surveys. 90 are a standard component of a comprehensive national HIV surveillance portfolio. 91 Several complementary ongoing initiatives consolidate HIV data on key populations to 92 support programme planning and implementation, global advocacy, and research. 93 These include the Key Population Atlas and Global AIDS Monitoring (Joint United 94 Nations Programme on HIV/AIDS [UNAIDS]), databases maintained by the US Centers 95 for Disease Control and Prevention (CDC) and the Global Fund Against TB, AIDS, and 96 Malaria (The Global Fund), and the Global. HIV initiative (Johns Hopkins University). 97 These include similar data sources, but vary in scope, inclusion criteria, data elements 98 recorded, and linkage to and validation against primary source data sets and reports. 99 Incomplete recording of key methodological details limits appraisal and formal evidence 100 synthesis, and therefore utility of data for strategic planning. 101 Many other research studies have systematically reviewed, analysed, and extrapolated 102 key population survey data in sub-Saharan Africa in single countries or across multiple 103

countries. These studies have tended to focus on specific outcomes or population groups of interest, and primarily comprise an appraisal of peer-reviewed literature.

Added value of this study

We consolidated and deduplicated data collected between 2010-2022 from existing key population surveillance databases maintained by the UNAIDS Key Population Atlas, UNAIDS Global AIDS Monitoring, US CDC, and the Global Fund. We used the Johns Hopkins University Global.HIV repository of surveillance reports, additional web-based searches, and engagement with country HIV strategic information teams to obtain survey reports in the peer-reviewed and grey literature, and validated each observation of key population size, HIV prevalence, or ART coverage against primary surveillance reports. We used regression analyses to characterise the relationship between key population and total population HIV indicators and extrapolated key population size estimates (KPSE), HIV prevalence, and ART coverage data to national-level estimates for all countries in mainland SSA.

This exercise was the most comprehensive effort to date to consolidate key population HIV data in SSA. We analysed 114 KPSE, 198 HIV prevalence, and 56 ART coverage studies. We estimated that across urban populations in SSA countries aged 15-49, a median of 1.71% of women were FSW; 0.92% of men have sex with men; 0.32% of men injected drugs; and 0.14% of women were transgender. This translated to 3.4 million FSW, 2 million MSM, 870,000 PWID, and 380,000 transgender women (TGW) in SSA who require comprehensive HIV prevention or treatment services. FSW, MSM, PWID, and TGW combined were estimated as 1.3% of the population aged 15-49, but

comprised 6.3% of people living with HIV. ART coverage among members of key populations living with HIV increased with total population ART coverage, but was lower for all key populations. We identified large gaps in data availability. Of the four key populations and three indicators studied, only Mozambique had data for all twelve indicators. Data were particularly sparse for transgender populations and PWID.

Implications of all the available evidence

Key populations experience HIV prevalence and lower ART coverage across all settings in sub-Saharan Africa than the total population. Extrapolated national estimates provide a foundation for planning appropriate key population-focused services for HIV prevention and treatment in all settings, including those with no or limited data.

However, large data availability gaps, inconsistency of existing data, and consequent wide uncertainty ranges around estimates limit the ability of existing data to guide granular programmatic planning and target setting for key population services and to monitor trends. More consistent surveillance implementation and improved routine surveillance through HIV prevention and treatment programmes for key populations would support monitoring equitable and equal programme access, as outlined in the Global AIDS Strategy 2021-2026 to end HIV/AIDS as a public health threat by 2030.

Introduction

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Key populations, including female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWID), and transgender women (TGW), experience high risk of acquiring and transmitting HIV due to a combination of biological and sociostructural factors, including stigma and criminalisation. 1-3 The Global AIDS Strategy 2021-2026 calls for "equitable and equal access" to HIV prevention and treatment to reduce HIV incidence and end HIV/AIDS as a public health threat by 2030.4 Delivering appropriate HIV services for these populations, and monitoring attainment of an equitable HIV response, requires robust epidemiologic and service engagement indicators, including key population size, HIV prevalence and incidence, treatment and prevention cascades. Key population surveys often rely on respondent-driven and venue-based sampling methods^{5,6} whose interpretation as population-representative relies upon strong assumptions that can be difficult to meet in practice. Household survey sampling frames are inappropriate for surveying migratory populations that are unlikely to disclose risk behaviour due to societal marginalisation and discrimination.^{7–9} Surveys are often infrequent and commonly restricted to, or disproportionately conducted in, urban areas. Consequently, data are sparse and less representative of a target population than standard general population sampling approaches such as national household surveys or sentinel surveillance. Systematic reviews and meta-analyses of population size, HIV prevalence, or antiretroviral treatment (ART) coverage encompassing sub-Saharan Africa (SSA) have

been conducted for FSW,^{10,11} MSM,^{12,13} PWID,^{14,15} and TGW.^{16,17} Several independent initiatives have been undertaken to consolidate key population surveillance data.^{18–21} These efforts aim to monitor the state of the epidemic, evaluate programmes, and make recommendations on key population data reporting and quality thresholds.

We consolidated and harmonised key population size estimates (KPSE), HIV prevalence, and ART coverage data from existing databases and described data availability across countries and over time for each key population. We characterised the relationship between key population and total population HIV indicators and extrapolated KPSE, HIV prevalence, and ART coverage data to national-level estimates for mainland countries in SSA.

Methods

Data sources and extraction

We consolidated data on KPSE, HIV prevalence, and ART coverage from four existing databases: Joint United Nations Programme on HIV/AIDS (UNAIDS) Global AIDS Monitoring submissions, ²² UNAIDS Key Population Atlas, ²³ the Global Fund to Fight AIDS, TB, and Malaria (the Global Fund) surveillance database, and a Microsoft Excel database maintained by the US Centers for Disease Control and Prevention (CDC) Division of Global HIV & TB Key Population Surveillance Team, and two systematic review databases ^{20,24} (Supplementary Table S1). For each observation, we extracted information about the study methodology, study location (country, subnational location), study population gender and age group, central estimate, sample size, standard error, and primary source or reference (e.g., survey report) (Supplementary Table S2).

Source documents were compiled from archives accompanying each database, the Johns Hopkins University Global.HIV document repository, ²⁵ Medline, and Google Scholar, following which we contacted UNAIDS Strategic Information advisors and other HIV programme contacts in each country to seek missing reports. Four authors (OS, RA, EG, AS-B) reviewed source documents to deduplicate observations recorded in multiple databases, validate against sources, and extract missing data elements. During source review, we added observations when additional relevant data were reported or additional sources were ascertained that were not in the initial databases.

Observations were excluded if: key population definition, year, or study area were missing; the study area was non-specific (e.g., 'urban areas' or '5 provinces'); estimates were modelled or extrapolated; or data could not be confirmed by primary source review. Studies were not excluded or differentiated in our analysis according to study-specific population group definitions based on engaging in risk behaviours or time periods (e.g. sold sex in the last 6 months versus last 12 months; Supplementary Text S1). Transgender men (TGM) were not analysed due to insufficient population size, HIV prevalence, or ART coverage data.

Data processing

To facilitate comparison of population sizes across settings, KPSE reported as counts were converted to population proportions for subnational locations in which key population surveys were conducted. Each KPSE was matched to the total population denominator by age, gender, year, and area. String matching was used to assign each

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

survey area to geographic boundaries from the Global Rural/Urban Mapping Project (GRUMP) or UNAIDS Naomi subnational district populations. 26-28 Age information was missing from nearly all key population reports; missing data was assigned age 15-49 years. Unless gender was specified, sex workers were assumed to be women, PWID assumed to be men. Surveys among transgender people which did not report gender were assumed to be among transgender women because respondents often reported high prevalence of male partners and receptive anal sex. and surveys among TGM in SSA remain rare. 17 KPSE methods were classified into five categories: two-source capture-recapture (2S-CRC), three-source capture-recapture (3S-CRC); [PLACE] and programmatic/hotspot mapping:²⁹ network scale-up (NSUM); and successive sampling population size estimates (SS-PSE). Two additional categories were defined for "Multiple methods – empirical" or "Multiple methods – mixture". KPSEs derived by solely non-empirical methods were excluded from analyses. Further details are in Supplementary Text S2. Key population HIV prevalence and ART coverage observations were compared to total population HIV prevalence or ART coverage, respectively, matched by age, gender, year, and first administrative level (henceforth 'province'). Province-level age/genderspecific HIV prevalence and ART coverage were extracted from UNAIDS Naomi subnational estimates for 2022^{26,27} and projected backwards 2000-2021 parallel to national HIV prevalence and ART coverage trajectories among adults 15-49 years.³⁰

Key population ART coverage observations among only persons who self-reported being aware of HIV positive status or used clinic-based recruitment were excluded. ART usage was determined through either self-report or laboratory methods via antiretroviral metabolite biomarker or viral load testing. Viral load suppression (VLS) observations were converted to estimates of ART coverage assuming 90% VLS among those on ART.

Analysis

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

We used Bayesian mixed-effects linear regression to model logit-transformed KPSE proportions among the urban total population aged 15-49 at the first administrative (e.g., province) level. Separate regressions were estimated for each key population. The model included effects for study method, spatially correlated national random provincelevel effects between neighbouring countries and provinces, and a study-level random effect allowing correlation among KPSE proportions at multiple subnational locations from the same study. The study method fixed effect was collapsed to two levels: (1) a pooled reference category of methods that estimated total key population size (2S-CRC, 3S-CRC, SS-PSE, and NSUM); and (2) PLACE/mapped estimates which counted venue- or hotspot-attending population size. Nested method random effects permitted method-specific deviation from the fixed effect. National KPSE counts were extrapolated using urban KPSE proportions, the proportion of the population living in urban areas.³¹ and the rural-to-urban ratio of key population size in urban and rural areas. Qualitative data indicate that KPSE proportions are higher in urban areas than rural areas, but no empirical data were available to quantify the rural-to-urban ratio.32-34 To allow wide

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

uncertainty in the rural-to-urban ratio, we assumed a Beta(5,3) distribution which had mean ratio of 0.6 and 80% of the mass between 0.4 and 0.8. For HIV prevalence, we modelled the relationship between logit-transformed key population HIV prevalence and logit total population HIV prevalence (age 15-49 years). FSW and PWID were modelled separately. Due to limited data, MSM and TGW were modelled together. To Survey HIV prevalence observations were modelled with a betabinomial distribution to allow overdispersion. Missing testing denominators for HIV prevalence observations were conservatively imputed using the 25th-percentile of observed denominators (imputed denominators: FSW n=127; MSM n=69; PWID n=74; TGW n=32). The model included fixed effects for logit population prevalence interacted with region (eastern and southern Africa [ESA] or western and central Africa [WCA]), a fixed effect for whether HIV status was self-reported or via HIV diagnostic tests, and province-, country-, and study-level random effects. The MSM-TGW model included a fixed effect for population type (TGW vs. MSM). Country- and province-level random effects were spatially correlated. Studies that omitted whether HIV prevalence was selfreported or diagnostically confirmed were assumed to be self-reported. Primary analysis for key population ART coverage, was restricted to diagnostically confirmed ART usage (either via ARV biomarker or VL testing). Logit-transformed key population ART coverage was modelled as a function of logit total population ART coverage in the same year, age group, and province. All key populations were modelled

together with random slopes for each key population to enable sharing of information

about the overall relationship for groups with very limited data. The observed number on

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

ART was modelled with a beta-binomial distribution with fixed effect terms for logit population ART coverage, spatially correlated country- and province-level random effects, and study-level random effects. Missing testing denominators were imputed using the 25th-centile of known denominators (imputed denominators: FSW n=40; MSM n=16; PWID n=13; TGW=12). We conducted sensitivity analyses which included self-reported ART coverage data with a fixed effect for self-reported versus diagnostically confirmed ART coverage. For all three models (KPSE, prevalence, ART coverage), in sensitivity analysis we used ages 15-29 years as the matched total population denominator for MSM and TGW regression analyses, reflecting the young median age of MSM and TGW survey respondents. 35,36 We combined national KPSE, HIV prevalence, and ART coverage estimates to calculate the number of KPLHIV and on ART. 95% uncertainty ranges were generated by combining 1000 posterior samples for each outcome. KPLHIV estimates were compared with 2022 national UNAIDS estimates³⁷ for age 15-49 years to calculate the proportion of PLHIV who were members of each key population. Data were extracted, deduplicated, and validated in Microsoft Excel. Statistical analyses were conducted in R version 4.2.0 using the R-INLA package (v23.4.24). Further statistical methods details are in Supplementary Text S3. The GATHER reporting checklist³⁸ is in Supplementary Table S14.

Ethics statement

291

292

293

294

297

298

299

300

302

303

304

305

306

307

309

310

311

This study received ethical approval from the Imperial College Research Integrity and

Governance Team (ICREC #6412027). Regulatory bodies providing ethical approvals or

other ethics considerations for included studies are reported in Supplementary File S3.

295 Role of the funding source

296 Authors KS, SA-G, MB, and MM are employees of UNAIDS and contributed to the

conceptualisation of the study, interpretation of results, and editing the manuscript. OS,

RA, and JWI-E had access to all data included in the study. OS and JWI-E accept

responsibility to submit for publication.

Results

301 Key population survey data availability

4215 KPSE conducted between 2010 to 2022 were compiled (Table 1). Following data

cleaning, source document review, and area matching, 2062 observations were

extracted from 114 studies (Figure 1). Data were most available for FSW (n=959, data

from 33/39 countries), followed by MSM (n=664, 30/39 countries), PWID (n=380, 19/39

countries), and TGW (n=110, 11/39 countries). No size estimates were available for

transgender men.

KPSE studies have become more common since 2010 (Figure 2). Between 2019-2021,

22 FSW, 17 MSM, 10 PWID, and 8 TGW PSE studies were conducted, increasing from

11, 11, 3, and 0, respectively, in 2010-12 (Figure 2). Seventy-two percent (470/654) of

urban MSM population proportion observations were below 1% of the male adult (15-

- 49y) population (the UNAIDS/WHO guidance for minimum MSM PSE proportions; 78% [280/360] in ESA and 65% [190/294] in WCA; Supplementary Figure S1).
- We identified 2416 key population HIV prevalence estimates (Table 1; Supplementary
- File 2), from which 1243 were extracted from 198 studies after processing.
- Denominators were reported for 87% (1082/1243) of observations. Most data were
- available for FSW (n=665, 36/39 countries), followed by MSM (n=362, 32/39 countries),
- ³¹⁸ PWID (n=145, 19/39 countries), TGW (n=74, 20/39 countries), and TGM (n=5, 5/39
- countries). 92% (1137/1243) of HIV prevalence observations were diagnostically
- 320 confirmed.
- For ART coverage, 561 observations were identified (Table 1). After processing, 201 observations were extracted from 56 studies. Denominators were available for 99%
- (199/201). Data were most available for FSW (n=121, 26/39 countries), followed by
- 324 MSM (n=71, 23/39), TGW (n=16, 9/39 countries) and PWID (n=11, 7/39 countries). No
- data were available for TGM. The percentage that were diagnostically-confirmed varied
- 326 by methodology (57% VLS [125/201]; 8% ART metabolite testing [17/201]; 35% self-
- ³²⁷ reported ART usage [77/201]).
- 328 Extrapolated urban key population size estimates
- Across national urban populations, a median of 1.71% women aged 15-49 years were
- FSW (interquartile range [IQR] 1.21-1.97%), 0.92% of men had sex with men (IQR 0.73-
- 331 1.01%), 0.32% of men injected drugs (IQR 0.28-0.39%) and 0.14% of women were
- transgender (IQR 0.12-0.17%; Figure 3). Incorporating the rural-to-urban ratio, median
- proportions of national total populations were 1.34% FSW, 0.71% MSM, 0.27% PWID,

- and 0.12% TGW. In sensitivity analysis, using age 15-29 years as a denominator for MSM PSEs, the urban proportion was 1.45% (IQR 1.10-1.58%; Supplementary Figure S2).
- Urban KPSE proportions were higher in ESA than WCA among FSW (ESA: 1.77%, IQR 337 1.51-2.08%; WCA 1.45%, IQR 1.07-1.83%) and MSM (ESA: 0.99%, IQR 0.93-1.23%; 338 WCA: 0.73%, IQR 0.69-0.94%). Proportions were similar between regions among PWID 339 and TGW, but KPSE data were sparse overall. PSE proportions derived from PLACE 340 and mapping studies were significantly lower than those derived from other methods 341 among FSW (log odds ratio -0.54; 95%CI: -0.93, -0.16), MSM (-1.38; 95%CI: -1.82, -342 0.95), and PWID (-1.13; 95%CI: -1.69, -0.55), and lower among TGW (-1.17; 95%CI: -343 2.43, 0.14) (Supplementary Table S4; Supplementary Figure S3). Supplementary 344
- 346 HIV prevalence among key populations

345

Tables S9-S12 report country-specific KPSE proportions.

- Most key population HIV prevalence observations were higher than area-matched total population HIV prevalence (FSW 91% [of observations 607/665]; MSM 85% [305/362]; PWID 85% [123/145]; TGW 85% [63/74]). Logit key population HIV prevalence in ESA was more strongly correlated with matched logit total population HIV prevalence than in WCA (ESA: FSW R=0.43, MSM R=0.51, PWID R=0.39, TGW R=0.42; WCA: FSW R=0.30, MSM R=0.29, PWID R=0.18, TGW R=0.14).
- Relative HIV prevalence differentials between key population and total population were
 larger when population prevalence was lower (Figure 4). For example, in ESA, 1% total
 population prevalence corresponded to 14% prevalence among FSW (95% prediction

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

range 10-20%), 5% among MSM (3-8%), 16% among PWID (9-27%), and 7% among TGW (3-16%). Fifteen percent population HIV prevalence corresponded to 49% HIV prevalence among FSW (39-59%), 20% among MSM (13-31%), 28% among PWID (15-45%), and 23% among TGW (15-33%). In WCA, relative patterns were similar, but key population HIV prevalence varied less with total population HIV prevalence than in ESA. Supplementary Table S5-S7 report regression results and Supplementary Table S11 reports country-specific estimates. ART coverage among key populations ART coverage among FSW, MSM, PWID, and TGW was correlated with gendermatched population ART coverage (logit-scale R=0.46, 0.35, 0.56, and 0.42 respectively; Figure 5). At 40% population ART coverage, predicted ART coverage among FSW was 5% lower (95% prediction range 13% lower to 4% higher), among MSM was 1% higher (8% lower to 10% higher), among PWID was 4% lower (17% lower to 12% higher), and among TGW was 6% lower (19% lower to 8% higher). At 80% population coverage, predicted ART coverage among FSW was 11% lower (20-1%) lower), among MSM 11% lower (20–1% lower), among PWID 13% lower (41% lower to 9% higher), and among TGW 30% lower (44–16% lower). Supplementary Table S8 reports regression results and S11 reports country-specific estimates. In sensitivity analysis including a fixed effect for ART measurement method, selfreported ART was lower than lab-confirmed ART (odds ratio 0.77, 95% CI 0.52-1.12; Supplementary Figure S4 and Table S8). Assuming MSM surveys represented MSM

aged 15-29 years had minimal impact on HIV prevalence or ART coverage estimates among MSM (Supplementary Table S13).

Disproportionate HIV burden among key populations in SSA

Across SSA, FSW, MSM, PWID, and TGW combined were 1.3% (95%CI: 0.9-1.7%) of the population aged 15-49 years (3.4m FSW, 2.0m MSM, 870,000 PWID, and 380,000 TGW), but 6.3% (4.6-8.6%) of PLHIV aged 15-49 years. In ESA this was 5.0% (3.6-7.0%) of PLHIV compared to 1.3% (0.9-1.9%) of the population and, in WCA, 12.0% (8.4-17.4%) of PLHIV compared to 1.2% (0.9-1.7%) of the population. FSW were 3.8% (2.5-5.4%) of PLHIV in SSA (710,000 PLHIV; 470,000-1,000,000), MSM were 1.5% (1.0-2.4%) or 290,000 PLHIV (190,000-450,000), PWID were 0.5% (0.3-1.0%) or 99,000 PLHIV (55,000-190,000), and TGW were 0.4% (0.2-1.0%) or 79,000 PLHIV (34,000-200,000) (Figure 6).

Discussion

Data from 247 key population surveys provided consistent evidence of key populations at disproportionately high risk of HIV acquisition and transmission in all countries in sub-Saharan Africa. We estimated there are 3.4m FSW, 2.0m MSM, 870,000 PWID, and 380,000 TGW in SSA who require comprehensive HIV prevention or treatment services. HIV prevalence among FSW was estimated to be 21%, 14% among MSM, 11% among PWID, and 20% among TGW. These were 4.6, 5.9, 4.6, and 4.4 times higher than population prevalence, respectively, with larger relative differences when population prevalence was lower. Together, these populations constituted 1.3% of the adult population in SSA but 6.3% of PLHIV. ART coverage among key populations increased

consistently with total population coverage, but lagged behind at high levels. However, there was wide uncertainty about estimates aggregated within countries and across SSA.

This exercise highlighted major data gaps and challenges interpreting existing data. Across the twelve combinations of four key populations and three indicators analysed here, countries had data for six combinations on average and three countries lacked any data (Supplementary Table S3). Data availability gaps widen further when selecting the highest quality and most recent data. These gaps impede delivery of equitable and equal access to HIV services and will remain without firm commitments to regularly collect key population survey data, likely including significant change to entrenched discriminatory practices and punitive laws and policies against key populations. ^{3,39–41} In settings lacking or with limited data, our extrapolated estimates should be a foundation with which to guide future surveillance priorities, stimulate in-country data review and use, and estimate HIV epidemic indicators. Future efforts should especially focus on strengthening surveillance for MSM, PWID, and transgender populations, and strengthening use of HIV service delivery data for all key populations, while ensuring the safety and protection of marginalised individuals and their communities.³

Previous key population reviews and meta-analyses^{11,42–44} relied on systematic searches of peer-reviewed literature. Our initial sources were existing databases, primarily populated by surveillance teams in each country or implementing organisations. This resulted in including a larger grey literature body, such as survey reports, which are infrequently indexed by peer-reviewed databases.⁴⁵ However, many

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

observations from initial databases (3% of PSE data, 31% of HIV prevalence data, 36% of ART coverage data) could not be validated from source documents and were excluded from this analysis, which in some countries excluded the only reported data. Demand for total population HIV estimates in SSA has promoted high-quality comparable surveillance methods, documentation, and dissemination. Review of key population data by national HIV surveillance teams was introduced into the UNAIDS sub-Saharan African estimates process in 2023, providing context for existing surveys, identifying missing sources and adding new data. This, alongside ongoing key population data initiatives and concerted advocacy efforts that ensure public dissemination, will improve the foundation for HIV surveillance among key populations and promote parity for key populations within national HIV data and strategic information. Systematically collated data on key population size, HIV prevalence, and ART coverage are critical inputs for mathematical modelling analyses that guide optimisation of HIV interventions. Such studies consistently demonstrate that fully meeting the HIV prevention and treatment needs of key populations has a disproportionately large impact on reducing overall population incidence due to network effects of averting further onward transmission over time and to non-key population partners. 46,47 Modelbased counterfactual indicators that capture these impacts, such as the transmission preventable attributable fraction, are a better basis for intervention prioritisation that simple population proportions reported in survey data. 46,48,49 46,4748,4950-5354-57

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

We estimated that 0.27% of men in SSA injected drugs, lower than estimates from Degenhardt et al. of 0.38%.58 This may reflect incorporating the urban-to-rural ratio in national PSE extrapolation in this analysis. We estimated that 1.4% of women aged 15-49 years sold sex, slightly higher than 1.1% estimated by Laga et al.⁵⁹ Our finding of heterogeneous HIV prevalence ratios between MSM and the total population was consistent with Hessou et al. 60, particularly in WCA where HIV burden in neighbouring countries can vary considerably. Our estimate of 62% ART coverage among MSM in 2022 was lower than 73% from a meta-analysis by Stannah et al. 61 of studies conducted up to 2022. This may be due to exclusion of self-reported ART usage in this analysis. Population size estimates measured in the same population at different times or with multiple methods were highly heterogenous, limiting data use for establishing meaningful programmatic targets or monitoring temporal trends. Very large uncertainty ranges around population size and PLHIV modelled estimates were consistent with findings of other statistically summarised and extrapolated PSE from multiple sources. 50-53 Non-existence of rural KPSE studies to empirically inform rural-urban population proportions contributed to five-fold or greater relative uncertainty in extrapolated national estimates. Quality assessments of individual KPSE studies were not conducted as part of this analysis. Both systematically improving and evaluating study-specific implementation quality and methodological assumptions may reduce heterogeneity and increase the utility of KPSE data. 54-57,62 Seventy-two percent of MSM KPSE observations and 34/39 modelled urban MSM estimates were below 1% of the male adult (15-49) population which UNAIDS and WHO

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

recommended in 2020 as a minimum MSM population proportion. 63 The minimum threshold was specified to ensure that MSM were not overlooked due to lack of data. Variation in MSM proportions measured in PSE studies may reflect ability to engage in sexual behaviours, affected by legal and social environment and other factors, rather than differences in distribution of sexual preference. It is also uncertain whether MSM recruited in surveys, who are disproportionately young 12,13, are representative of the total MSM population (Supplementary Figure S2). Nonetheless, specifying a minimum 1% threshold for MSM population could result in unrealistic MSM-focused service targets. The threshold should be reconsidered with the wider range of data now available, aligned with risk-based approaches to quantifying sex work and injecting drug use. Study-specific quality assessments will be key to producing accurate KPSE given stigma experienced by MSM in many settings. Integrating key population programme data within key population estimates should be a priority to improve utility of surveillance data to guide programmatic response and monitor trends and subnational variation.⁶⁴ Triangulating routine HIV testing and treatment data with biobehavioural survey data may help disentangle programmatic double counting, coverage of key population-specific services, and accounting for linkage to care in the estimation of ART coverage and viral load suppression. 65-67 Future surveillance should consider moving beyond strictly defined key population definitions accurately to reflect heterogenous risks among individuals in overlapping risk environments including cisgender MSM and transgender women who sell sex, and FSW and MSM who inject drugs. 68-70

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

Several limitations should be considered when interpretating these data and estimates. Firstly, surveys used a range of key population definitions and inclusion criteria which limited comparability, though there was sufficient overlap (Supplementary Text S2). Second, lack of explicit geographic survey sampling frames made it challenging to define appropriate subnational population denominators for KPSE proportions: the urban extents derived from the Global Rural/Urban Mapping Project may not accurately reflect the catchment population for a given survey, particularly given the mobility of key populations.⁷¹ This likely exacerbates the observed heterogeneity in KPSE proportions (Figure 3B), and is a major limitation for extrapolating KPSE proportions for programmatic planning. Going forward, careful data quality assessments to determine study inclusion and interpretation, and specification of population catchments with key population surveillance reports will improve future data use. Third, sample size or standard errors and age ranges were omitted from most population size data entries. This limited ability to statistically weight or age-standardise data in model extrapolations. Finally, data were insufficient and too heterogeneous to estimate time trends in population proportions, HIV prevalence, or ART coverage. Application of standardised recruitment methods, population definitions, and indicator reporting in consistent locations will improve monitoring of trends. In conclusion, key populations across SSA experience disproportionate HIV burden and have lower antiretroviral treatment coverage. Consolidated key population data and synthesised estimates provide a basis for key population programming in all countries. including those with limited locally available data. Despite increasing focus on key populations in HIV/AIDS strategies in SSA, new surveillance strategies, improved use of

routine data, and more consistent surveillance implementation are required to furnish more precise estimates and trends for programme planning and support the monitoring of equitable and equal access to HIV prevention and treatment programmes outlined in the Global AIDS Strategy 2021-2026.

Authors' contributions

513

514

515

516

517

518

519

520

522

525

528

529

530

531

532

533

OS, KS, MM and JWI-E conceptualised the study. KS, SAG, JZ, AMcI, KW, LD curated key population survey databases. OS, RA, EG, AS-B reviewed primary source documents, deduplicated data, and extracted data. OS analysed the data and wrote the first draft of the manuscript. All authors contributed to interpretation of results and edited the manuscript for intellectual content. All authors read and approved the final version of the manuscript for submission.

Declaration of interests

521 < Insert declarations from author forms>

Disclaimer

The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the funding agencies.

Data sharing

Data extracted data for this analysis are available in spreadsheet format in

Supplementary File 2. R code to reproduce analysis is available from <insert URL>.

Acknowledgments

This research was supported by UNAIDS, Bill and Melinda Gates Foundation (INV-006733), National Institute of Allergy and Infectious Disease of the National Institutes of Health under award number R01AI136664, and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office

- (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2
- programme supported by the European Union. MM-G's research program is funded by
- a Canada Research Chair (Tier II) in Population Health Modeling.

References

- 1. UNAIDS. *The Gap Report.*; 2014.
- Garnett GP. Reductions in HIV incidence are likely to increase the importance of key population programmes for HIV control in sub□Saharan Africa. *J Int AIDS*Soc. 2021;24(S3):e25727. doi:10.1002/jia2.25727
- World Health Organization. Consolidated Guidelines on HIV, Viral Hepatitis and
 STI Prevention, Diagnosis, Treatment and Care for Key Populations.; 2022.
 http://apps.who.int/iris/bitstream/10665/128048/1/9789241507431_eng.pdf?ua=1
- United Nations. End Inequalities. End AIDS. Global AIDS Strategy 2021-2026 |
 UNAIDS. Published 2021. Accessed May 5, 2021.
- https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDSstrategy
- 5. Baneshi MR, Rastegari A, Haghdoost AA. Review of Size Estimation Methods. In:
 Advances in Experimental Medicine and Biology. Vol 1333. Springer; 2021:1-15.
 doi:10.1007/978-3-030-75464-8_1
- 552 6. Abdul-Quader AS, Baughman AL, Hladik W. Estimating the size of key
 553 populations: Current status and future possibilities. *Curr Opin HIV AIDS*.
 554 Published online 2014. doi:10.1097/COH.000000000000001

- Jin H, Restar A, Beyrer C. Overview of the epidemiological conditions of HIV among key populations in Africa. *J Int AIDS Soc.* 2021;24(S3).

 doi:10.1002/jia2.25716
- Hakim AJ, MacDonald V, Hladik W, et al. Gaps and opportunities: measuring the key population cascade through surveys and services to guide the HIV response.

 J Int AIDS Soc. 2018;21(Suppl Suppl 5):e25119. doi:10.1002/jia2.25119
- 9. Sabin K, Zhao J, Garcia Calleja JM, et al. Availability and quality of size
 estimations of female sex workers, men who have sex with men, people who
 inject drugs and transgender women in low- and middle-income countries. *PLoS*One. 2016;11(5). doi:10.1371/journal.pone.0155150
- 10. Atuhaire L, Adetokunboh O, Shumba C, Nyasulu PS. Effect of community-based interventions targeting female sex workers along the HIV care cascade in sub-Saharan Africa: a systematic review and meta-analysis. *Syst Rev.* Published online 2021. doi:10.1186/s13643-021-01688-4
- 11. Baral S, Beyrer C, Muessig K, et al. Burden of HIV among female sex workers in low-income and middle-income countries: A systematic review and meta-analysis.

 Lancet Infect Dis. Published online 2012. doi:10.1016/S1473-3099(12)70066-X
- 572 12. Stannah J, Dale E, Elmes J, et al. HIV testing and engagement with the HIV 573 treatment cascade among men who have sex with men in Africa: a systematic 574 review and meta-analysis. *Lancet HIV*. 2019;6(11):e769-e787.
 - doi:10.1016/S2352-3018(19)30239-5

- 576 13. Stannah J, Soni N, Keng J, et al. Trends in HIV testing, the treatment cascade, 577 and HIV incidence among men who have sex with men in Africa: A systematic 578 review and meta-regression analysis. *Lancet HIV*. Published online 2023. 579 doi:0.1016/S2352-3018(23)00111-X
- Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug
 use and HIV among people who inject drugs: a systematic review. *The Lancet*.

 Published online 2008. doi:10.1016/S0140-6736(08)61311-2
- Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug
 use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV
 in people who inject drugs: a multistage systematic review. *Lancet Glob Health*.
 2017;5(12):e1192-e1207. doi:10.1016/S2214-109X(17)30375-3
- 16. Kloek M, Bulstra CA, van Noord L, Al-Hassany L, Cowan FM, Hontelez JAC. HIV
 prevalence among men who have sex with men, transgender women and
 cisgender male sex workers in sub-Saharan Africa: a systematic review and
 meta-analysis. *J Int AIDS Soc.* 2022;25(11). doi:10.1002/JIA2.26022
- 591 17. Stevens O. HIV prevalence in transgender populations and cisgender men who
 592 have sex with men in sub-Saharan Africa 2010-2022: a meta-analysis. *medRxiv*.
 593 Published online 2023. doi:10.1101/2023.11.09.23298289
- 18. UNAIDS. Global AIDS Monitoring 2022. Published 2022. Accessed February 18,
 2022. https://www.unaids.org/en/global-aids-monitoring

- 19. UNAIDS, WHO. Recommended Population Size Estimates for Men Who Have
 Sex with Men.; 2020.
- 20. Rao A, Schwartz S, Sabin K, et al. HIV-related data among key populations to inform evidence-based responses: protocol of a systematic review. *Syst Rev.*Published online 2018.
- UNAIDS, FHI 360, WHO, CDC, PEPFAR. Biobehavioural Survey Guidelines For
 Populations At Risk For HIV.; 2017. Accessed February 17, 2022.
 http://apps.who.int/bookorders.
- UNAIDS. Global AIDS Monitoring 2022. Published 2022. Accessed February 18,
 2022. https://www.unaids.org/en/global-aids-monitoring
- UNAIDS. Key Populations Atlas. Accessed November 27, 2021.
 https://kpatlas.unaids.org/dashboard
- Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug
 use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV
 in people who inject drugs: a multistage systematic review. *Lancet Glob Health*.
 2017;5(12):e1192-e1207. doi:10.1016/S2214-109X(17)30375-3
- Rao A, Schwartz S, Sabin K, et al. HIV-related data among key populations to inform evidence-based responses: protocol of a systematic review. *Syst Rev.*Published online 2018.

- UNAIDS. HIV sub-national estimates viewer. Published 2021. Accessed May 12, 2022. https://naomi-spectrum.unaids.org/
- Eaton JW, Dwyer-Lindgren L, Gutreuter S, et al. Naomi: a new modelling tool for estimating HIV epidemic indicators at the district level in sub-Saharan Africa. *J Int*AIDS Soc. Published online 2021. doi:10.1002/jia2.25788
- 620 28. Global Rural-Urban Mapping Project (GRUMP). Urban boundaries. Accessed
 621 October 25, 2021. https://sedac.ciesin.columbia.edu/data/collection/grump-v1
- 29. Weir S. Priorities for Local AIDS Control Efforts (PLACE).; 2019.
- 30. Eaton JW, Brown T, Puckett R, et al. The Estimation and Projection Package

 Age-Sex Model and the r-hybrid model: New tools for estimating HIV incidence

 trends in sub-Saharan Africa. *AIDS*. 2019;33(Suppl 3):S235-S244.

 doi:10.1097/QAD.00000000000002437
- 31. Nations U, of Economic D, Affairs S, Division P. *World Urbanization Prospects*The 2018 Revision.: 2018.
- Maleke K, Makhakhe N, Peters RPH, et al. HIV risk and prevention among men who have sex with men in rural South Africa. *African Journal of AIDS Research*. 2017;16(1):31-38. doi:10.2989/16085906.2017.1292925
- 33. Wimark T. The City as a Single Gay Male Magnet? Gay and Lesbian
 Geographical Concentration in Sweden. 2014;752(September 2013):739-752.

- 34. Kobrak P, Ponce R, Zielony R. New Arrivals to New York City□: Vulnerability to
 HIV among Urban Migrant Young Gay Men. Arch Sex Behav. Published online
 2015:2041-2053. doi:10.1007/s10508-015-0494-4
- 35. Johnson LF, Mulongeni P, Marr A, Lane T. Age bias in survey sampling and implications for estimating HIV prevalence in men who have sex with men:

 Insights from mathematical modelling. *Epidemiol Infect*. 2018;146(8):1036-1042.

 doi:10.1017/S0950268818000961
- Stannah J, Dale E, Elmes J, et al. HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis. *Lancet HIV*. 2019;6(11):e769-e787.

 doi:10.1016/S2352-3018(19)30239-5
- UNAIDS. Global AIDS Update. Published 2021. Accessed May 12, 2022.
 https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update
- 38. Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent
 Health Estimates Reporting: the GATHER statement. *The Lancet*.

 2016;388(10062):e19-e23. doi:10.1016/S0140-6736(16)30388-9
- Lyons C, Bendaud V, Bourey C, et al. Global assessment of existing HIV and key population stigma indicators: A data mapping exercise to inform country-level stigma measurement. *PLoS Med.* 2022;19(2):e1003914.
 - doi:10.1371/JOURNAL.PMED.1003914

- 654 40. UNAIDS. Prevailing against pandemics by putting people at the centre. Published 655 online 2020.
- 41. HIV Policy Lab. HIV Policy Lab. Accessed October 25, 2023.
 https://www.hivpolicylab.org/
- Hessou PHS, Glele-Ahanhanzo Y, Adekpedjou R, et al. Comparison of the
 prevalence rates of HIV infection between men who have sex with men (MSM)
 and men in the general population in sub-Saharan Africa: A systematic review
 and meta-analysis. *BMC Public Health*. 2019;19(1):1634. doi:10.1186/s12889019-8000-x
- 663 43. Stutterheim SE, Van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in 664 transgender individuals: An updated systematic review and meta-analysis. *PLoS* 665 *One.* 2021;16(12 December). doi:10.1371/journal.pone.0260063
- Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug
 use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV
 in people who inject drugs: a multistage systematic review. *Lancet Glob Health*.
 2017;5(12):e1192-e1207. doi:10.1016/S2214-109X(17)30375-3
- 670 45. Stevens O. HIV prevalence in transgender populations and cisgender men who
 671 have sex with men in sub-Saharan Africa 2010-2021: a meta-analysis. Published
 672 online 2022.

- 673 46. Stone J, Mukandavire C, Boily M, et al. Estimating the contribution of key 674 populations towards HIV transmission in South Africa. *J Int AIDS Soc.* 675 2021;24(1):e25650. doi:10.1002/jia2.25650
- 47. Mishra S, Pickles M, Blanchard JF, Moses S, Boily MC. Distinguishing sources of HIV transmission from the distribution of newly acquired HIV infections: Why is it important for HIV prevention planning? Sex Transm Infect. 2014;90(1):19-25. doi:10.1136/sextrans-2013-051250
- 48. Mishra S, Pickles M, Blanchard JF, Moses S, Shubber Z, Boily MC. Validation of the modes of transmission model as a tool to prioritize HIV prevention targets: A comparative modelling analysis. *PLoS One*. 2014;9(7). doi:10.1371/journal.pone.0101690
- Shubber Z, Mishra S, Vesga JF, Boily MC. The HIV modes of transmission model:
 A systematic review of its findings and adherence to guidelines. *J Int AIDS Soc.*2014;17(1). doi:10.7448/IAS.17.1.18928
- 50. Edwards JK, Hileman S, Donastorg Y, et al. Estimating Sizes of Key Populations
 at the National Level: Considerations for Study Design and Analysis.
 Epidemiology. 2018;29(6):795-803. doi:10.1097/EDE.00000000000000906
- Niu XM, Rao A, Chen D, et al. Using factor analyses to estimate the number of female sex workers across Malawi from multiple regional sources. *Ann Epidemiol*. 2021;55:34-40. doi:10.1016/j.annepidem.2020.12.001

- 693 52. Fearon E, Chabata ST, Magutshwa S, et al. Estimating the Population Size of
- Female Sex Workers in Zimbabwe: Comparison of Estimates Obtained Using
- Different Methods in Twenty Sites and Development of a National-Level Estimate.
- 696 *J Acquir Immune Defic Syndr.* 2020;85(1):30-38.
- 697 doi:10.1097/QAI.000000000002393
- 53. Datta A, Lin W, Rao A, et al. Bayesian Estimation of MSM Population Size in Côte
- d'Ivoire. Statistics and Public Policy. 2019;6(1):1-13.
- doi:10.1080/2330443X.2018.1546634
- 701 54. Wesson PD, Mirzazadeh A, McFarland W. A Bayesian approach to synthesize
- estimates of the size of hidden populations: The anchored multiplier. *Int J*
- 703 Epidemiol. 2018;47(5):1636-1644. doi:10.1093/ije/dyy132
- 55. Fellows I. Consensus Estimate Calculator. Accessed April 11, 2022.
- 705 https://epiapps.com/shiny/app_direct/shinyproxy_combine_estimates/
- 56. USAID. Namibia Small Area Estimation: Final Report Small Area Estimation of
- Key Population Sizes in Namibia: Final Report.; 2021.
- ₇₀₈ 57. Datta A, Lin W, Rao A, et al. Bayesian Estimation of MSM Population Size in Côte
- d'Ivoire. Statistics and Public Policy. 2019;6(1):1-13.
- 710 doi:10.1080/2330443X.2018.1546634
- 58. Degenhardt L, Webb P, Colledge-Frisby S, et al. Epidemiology of injecting drug
- use, prevalence of injecting-related harm, and exposure to behavioural and

environmental risks among people who inject drugs: a systematic review. *Lancet*Glob Health. 2023;11(5):e659-e672. doi:10.1016/S2214-109X(23)00057-8

- Laga I, Niu X, Rucinski K, et al. Mapping the Population Size of Female Sex
 Worker in Countries Across Sub-Saharan Africa. *PNAS*. Published online
 September 19, 2023. doi:10.1073/pnas.2200633120
- 718 60. Hessou PHS, Glele-Ahanhanzo Y, Adekpedjou R, et al. Comparison of the
 719 prevalence rates of HIV infection between men who have sex with men (MSM)
 720 and men in the general population in sub-Saharan Africa: A systematic review
 721 and meta-analysis. *BMC Public Health*. 2019;19(1):1634. doi:10.1186/s12889722 019-8000-x
- of 1. Stannah J, Dale E, Elmes J, et al. HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis. *Lancet HIV*. Published online 2019.

 doi:10.1016/S2352-3018(19)30239-5
- 727 62. Rao A, Schwartz S, Viswasam N, et al. Evaluating the quality of HIV

 728 epidemiologic evidence for populations in the absence of a reliable sampling

 729 frame: a modified quality assessment tool. *Ann Epidemiol.* 2022;65:78-83.

 730 doi:10.1016/J.ANNEPIDEM.2021.07.009
- of 3. UNAIDS, WHO. Recommended Population Size Estimates for Men Who Have
 Sex with Men.; 2020.

- of USAID. Namibia Small Area Estimation: Final Report Small Area Estimation of Key Population Sizes in Namibia: Final Report.; 2021.
- 735 65. Scheibe AP. Still left behind: Using programmatic data to assess harm reduction 736 service coverage and HIV treatment cascades for people who inject drugs in five 737 South African cities. In: *IAS*.; 2019.
- Scheibe A, Grasso M, Raymond HF, et al. Modelling the UNAIDS 90-90-90
 treatment cascade for gay, bisexual and other men who have sex with men in
 South Africa: using the findings of a data triangulation process to map a way
 forward. AIDS Behav. 2018;22(3):853-859. doi:10.1007/s10461-017-1773-y
- Hakim AJ, MacDonald V, Hladik W, et al. Gaps and opportunities: measuring the key population cascade through surveys and services to guide the HIV response.

 J Int AIDS Soc. 2018;21(Suppl Suppl 5):e25119. doi:10.1002/jia2.25119
- 745 68. Syvertsen JL, Agot K, Ohaga S, Bazzi AR. You can't do this job when you are
 746 sober: Heroin use among female sex workers and the need for comprehensive
 747 drug treatment programming in Kenya. *Drug Alcohol Depend.* 2019;194:495-499.
 748 doi:10.1016/j.drugalcdep.2018.10.019
- Poteat T, Ackerman B, Diouf D, et al. HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis. *PLoS Med.*Published online 2017. doi:10.1371/journal.pmed.1002422

70. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide 753 burden of HIV in transgender women: A systematic review and meta-analysis. 754 Lancet Infect Dis. 2013;13(3):214-222. doi:10.1016/S1473-3099(12)70315-8 755 71. Davey C, Dirawo J, Mushati P, Magutshwa S, Hargreaves JR, Cowan FM. 756 Mobility and sex work: why, where, when? A typology of female-sex-worker 757 mobility in Zimbabwe. Soc Sci Med. 2019;220:322-330. 758 doi:10.1016/j.socscimed.2018.11.027 759 760 761

Figures and Tables




Figure 1: Flow diagrammes describing identified data for key population size estimates, HIV prevalence data, and key population ART coverage. Each *n* represents number of population/method/location observations, with potentially observations for multiple subnational locations from the same study in same country. ART: Antiretroviral coverage; FSW: Female sex worker; MSM: Men who have sex with men; PWID: People who inject drugs; TGW: Transgender women; KP: Key Population; GAM: Global AIDS Monitoring; CDC: US Centers for Disease Control and Prevention; PSE: Population size estimate.

Table 1: Availability of population size, HIV prevalence, and ART coverage data by key population and region during period 2010-2022.

| Region | Key population | Key Population Size Estimates (KPSE) | | HIV prevalence | | ART coverage | |
|--------------------------|-------------------|---|----------------------------|----------------|----------------------------|---------------|----------------------------|
| | | Observ ations | Countries with data (n; %) | Observ ations | Countries with data (n; %) | Observ ations | Countries with data (n; %) |
| SSA (39 countries) | FSW | 959 | 33 (85) | 665 | 36 (92) | 121 | 26 (67) |
| | MSM | 664 | 30 (77) | 362 | 32 (82) | 71 | 23 (59) |
| | PWID | 380 | 19 (49) | 145 | 19 (49) | 11 | 7 (18) |
| | TGW | 110 | 11 (28) | 74 | 20 (51) | 16 | 9 (23) |
| | TGM | 0 | 0 (0) | 5 | 4 (10) | 0 | 0 (0) |
| ESA (18 countries) | FSW | 552 | 17 (94) | 336 | 18 (100) | 77 | 14 (78) |
| | MSM | 365 | 14 (78) | 140 | 15 (83) | 38 | 12 (67) |
| | PWID | 238 | 7 (39) | 62 | 9 (50) | 6 | 4 (22) |
| | TGW | 68 | 6 (33) | 32 | 11 (61) | 13 | 7 (39) |
| | TGM | 0 | 0 (0) | 2 | 2 (5) | 0 | 0 (0) |
| WCA (21 countries) | FSW | 407 | 16 (76) | 329 | 18 (86) | 44 | 12 (57) |
| | MSM | 299 | 16 (76) | 222 | 17 (81) | 33 | 11 (52) |
| | PWID | 142 | 12 (57) | 83 | 10 (48) | 5 | 3 (14) |
| | TGW | 42 | 5 (24) | 42 | 9 (43) | 3 | 2 (10) |
| | TGM | 0 | 0 (0) | 3 | 3 (8) | 0 | 0 (0) |

SSA: Sub-Saharan Africa; ESA: East and Southern Africa; WCA: Western and Central Africa; FSW: female sex workers; MSM: men who have sex with men; PWID: people who inject drugs; TGW: transgender women; TGM: transgender men; KPSE: key population size estimate; ART: antiretroviral therapy





Figure 2: Distribution of size estimation methods implemented over time by key population. The number of size estimation studies is shown above the bars. Bars are colour coded by method empiricism from highest (3S-CRC) to lowest (non-empirical).

3S-CRC: Three-source capture-recapture; 2S-CRC: Two-source capture-recapture; SS-PSE: Successive sampling population size estimate; NSUM: network scale-up method; PLACE: Priorities for Local AIDS Control Efforts






Figure 3: Model estimated urban key population size estimate (KPSE) proportions for female sex workers, men who have sex with men, people who inject drugs, and transgender women as a proportion of gender-matched 15-49 years adult total population. (A) Posterior median estimate for each country. Note: colour range is different for each key population chloropleth. (B) Posterior median estimate and 95% credible intervals for each country. Points represent observations of subnational KPSE proportions that used empirical methods. Countries that had local surveillance data are shown in blue, and countries informed only by spatial smoothing from neighbouring countries in yellow. Vertical axis shown on log-scale.




Figure 4: Key population and total population HIV prevalence on the logit scale (A), natural scale (B), and expressed as a ratio of key population and total population prevalence (C) for female sex workers, men who have sex with men, people who inject drugs, and transgender women. Coloured points indicate observed key population prevalence plotted against gender/year/province-matched total population prevalence. Coloured lines and shading represent regional estimate and 95% uncertainty results. Points represent country estimates [filled for countries with HIV prevalence data and empty for countries without HIV prevalence data] and 95% uncertainty ranges. Dotted line represents line of equality.





Figure 5: Estimated key population ART coverage as a function of total population ART coverage on the estimated logit scale (upper) and natural scale (lower). Coloured points indicate observed key population prevalence plotted against gender/year/province-matched total population ART coverage. Black line and shading represent estimate for sub-Saharan Africa and 95% uncertainty results. Black points represent country estimates and 95% uncertainty ranges. Dotted line represents line of equality.

802

803

804

805






Figure 6: (A) HIV positive key population members as a proportion of all PLHIV aged 15-49 years. Countries are ordered geographically. (B) Estimated number of key populations living with HIV (KPLIV) in Eastern and Southern Africa and Western and Central Africa.

807 808

809

810